Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003
Observational
Time Perspective: Retrospective
Participants Survival Status as of the Time of the Extension Study Follow-up
Count of participants who were alive or deceased at the time of the extension study follow-up.
up to 7 years
No
Barry Skikne, MD
Study Director
Celgene Corporation
United States: Institutional Review Board
CC-5013-MDS-009
NCT01099267
March 2010
October 2010
Name | Location |
---|---|
Wake Forest University | Winston-Salem, North Carolina 27103 |
Fred Hutchinson Cancer Research Center | Seattle, Washington 98109 |
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
H. Lee Moffitt Cancer Center | Tampa, Florida 33612 |
University of Chicago | Chicago, Illinois 60637 |
The Cleveland Clinic Foundation | Cleveland, Ohio |
Hematology Oncology Associates of Illinois | Skokie, Illinois 60077 |
Northwest Georgia Oncology Centers, P.C. | Marietta, Georgia 30060 |
Cancer & Blood Disease Center | Lecanto, Florida 34461 |
Mayo Clinic - Rochester | Rochester, Minnesota 55905 |
Stanford University Cancer Center | Stanford, California 94305 |
Mayo Clinic - Scottsdale | Scottsdale, Arizona 85259 |
John Hopkins University Hospital | Baltimore, Maryland 21231 |